Eli Lilly discontinues Ph II trials for arthritis drug
In March 2015, Hanmi signed an exclusive license agreement with the US-based drug maker to grant rights to HM71224 in a deal that could generate up to $640 million
K...
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.